Tyvense 20mg, 30mg, 40mg, 50mg. 60mg & 70mg Capsules, hard
- Name:
Tyvense 20mg, 30mg, 40mg, 50mg. 60mg & 70mg Capsules, hard
- Company:
Shire Pharmaceuticals Ireland Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/11/20
(Click to Download)Click on this link to Download PDF directly
Shire Pharmaceuticals Ireland Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 19 November 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
Section |
Changes (in red) |
||||||||||
|
4.4 Special warnings and precautions for use
|
Addition of the following text: Lisdexamfetamine has shown to prolong the QTc interval in some patients. It should be used with caution in patients with prolongation of the QTc interval, in patients treated with drugs affecting the QTc interval, or in patients with relevant pre-existing cardiac disease or electrolyte disturbances. |
||||||||||
|
4.8 Adverse events |
Addition of the following adverse event:
|
||||||||||
|
10 Date of revision of the text |
11th November 2020 |
Updated on 19 November 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to date of revision
Updated on 11 December 2019 SPC
Reasons for updating
- Removal of Black Inverted Triangle
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Removal of the black triange
Updated on 11 December 2019 PIL
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
Free text change information supplied by the pharmaceutical company
Removal of Black triangle
Section 2 - addition of sodium excipient warning
Section 4- updated ADR reporting details
Please also note that texts have been combined into one QRD document for all strengths. Grey highlights indicate the differences between texts for the 20, 40, 60mg vs 30, 50, 70mg strengths, as two separate artworks exist , one for the 20, 40, 60mg and another for 30, 50, 70mg strengths.
Section 6- las revised changed from 10/2018 to 11/2019
Updated on 11 December 2019 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 Pre-treatment evaluation has been moved up from under method of administration to under posology and method of administration
The elderly section has been removed
Information from the use in adults section has been removed
The following has been added to the Excipients section "This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free’"
Section 4.7- Diplopia has been removed
Section 10- Date of revision has been amended from Oct 2018 to 1st Dec 2019
Updated on 6 November 2018 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Company name change or merger
Updated on 5 November 2018 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Company name change or merger
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 7 (Marketing Authorisation Holder): MAH transfer of MAH name and address - from Shire Pharmaceutical Contracts Limited, One Kingdom Street, W2 6BD, London, United Kingdom to Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland
Section 8 (Marketing Authroisation numbers): New numbers due to the MAH transfer
Updated on 16 July 2018 SPC
Reasons for updating
- Addition of joint SPC covering all presentations
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The Summary of Product Characteristics has been updated to cover all licensed strengths (20, 30, 40, 50, 60 and 70mg capsules). Consequently sections 1, 2, 3, 6.1 8 and 10 have been updated.
Updated on 27 April 2018 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 13 April 2018 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 19 February 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 19 February 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 19 February 2018 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
In section 5.2 (Pharmacokinetic properties), the section on special populations has been clarified concerning administration in children
In section 4.1 (indication) "DSM IV" and "ICD 10" have been replaced by "DSM" and "ICD" respectively
Updated on 19 February 2018 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 22 November 2016 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 17 November 2016 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 28 October 2016 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 27 October 2016 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 4 August 2016 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.5 Interaction with other medicinal products and other forms of interaction
addition of the following wording:
Serotonergic drugs
Serotonin syndrome has rarely occurred in association with the use of amphetamines such as Tyvense, when given in conjunction with serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). It has also been reported in association with overdose of amphetamines, including Tyvense (see section 4.9).
Updated on 27 April 2015 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
To update the date of revision of hte text to April 2015.
Updated on 11 February 2015 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.5 has been updated with clarification text.
Section 4.8 has been updated with Raynaud’s phenomenon.
Section 4.9 has been updated with clarification text.
Section 5.2 with PK study.
Updated on 10 February 2015 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
- Change to dosage and administration
Updated on 9 February 2015 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8 (undesirable effects): Summary of safety profile updated: Very common adverse reactions include decreased appetite, insomnia, dry mouth, headache and weight decreased and upper adnominal pain.
Section 4.8 (undesirable effects): Several updates to the tabulated summary of adverse effects as follows:
- Anorexia deleted as adverse reaction
- Anxiety changed from uncommon to common (adolescents only)
- Psychomotor activity changed from common to uncommon (children only)
- Restlessness changed from uncommon to common (adolescents only)
- Somnolence changed from uncommon to common (adolescents only)
- Dyskinesia changed from frequency not known to uncommon (children only)
- Mydriasis changed from common to uncommon (children only)
- Raynaud’s phenomenon added as adverse reaction
- Constipation added as adverse reaction
- Upper abdominal pain changed from very common to common (children only)
- Hyperhidrosis changed from frequency not known to uncommon (adolescents only)
- Feeling jittery changed from uncommon to common (adolescents only)
Section 10 (date of revision of the text): Date has been updated.
Updated on 9 February 2015 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 22 July 2014 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
- Addition of black triangle
Updated on 18 July 2014 SPC
Reasons for updating
- Addition of black triangle
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The following sections of the SPC are updated:
Black triangle: Addition of black triangle detailing that the product is subject to additional monitoring and details for how to report adverse reactions have been included in Section 4.8.
Section 4.8 (undesirable effects): Bruxism added as an adverse reaction.
Section 5.1 (pharmacodynamic properties): The results of a recently completed study has been added to this section (See “A double-blind, randomised, active-controlled, dose-optimisation study was conducted in children and adolescents aged 6 to 17 years (n=267) who met DSM-IV criteria for ADHD”).
Section 10: Date of the revision of the text has been updated.
In addition to the changes above, the following amendments were also made:
Section 4.1 (indication): Correction of typographical error: "aged 6 years of age and over"
Section 4.2 (Posology and method of administration): Update to text: “For all patients, either starting treatment for ADHD or switching from another medication, the starting dose is 30 mg taken once daily in the morning."
Section 5.1 (pharmacodynamic properties): The design of Study SPD489-325 has been clarified "dose-titrated" replaced with “dose-optimised”.
Updated on 1 July 2013 PIL
Reasons for updating
- New PIL for new product
Updated on 28 June 2013 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)